company background image
IKNA

Ikena Oncology NasdaqGM:IKNA Stock Report

Last Price

US$5.07

Market Cap

US$183.8m

7D

-2.9%

1Y

-55.5%

Updated

17 Aug, 2022

Data

Company Financials +
IKNA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IKNA Stock Overview

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs.

Ikena Oncology, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ikena Oncology
Historical stock prices
Current Share PriceUS$5.07
52 Week HighUS$17.50
52 Week LowUS$2.83
Beta0
1 Month Change-1.17%
3 Month Change37.03%
1 Year Change-55.49%
3 Year Changen/a
5 Year Changen/a
Change since IPO-84.16%

Recent News & Updates

Aug 06
Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth

Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Shareholder Returns

IKNAUS PharmaceuticalsUS Market
7D-2.9%0.3%4.5%
1Y-55.5%-0.9%-8.9%

Return vs Industry: IKNA underperformed the US Pharmaceuticals industry which returned -0.9% over the past year.

Return vs Market: IKNA underperformed the US Market which returned -8.9% over the past year.

Price Volatility

Is IKNA's price volatile compared to industry and market?
IKNA volatility
IKNA Average Weekly Movement17.0%
Pharmaceuticals Industry Average Movement12.1%
Market Average Movement7.6%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: IKNA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: IKNA's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201679Mark Manfredihttps://ikenaoncology.com

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer.

Ikena Oncology, Inc. Fundamentals Summary

How do Ikena Oncology's earnings and revenue compare to its market cap?
IKNA fundamental statistics
Market CapUS$183.83m
Earnings (TTM)-US$49.05m
Revenue (TTM)US$27.73m

6.6x

P/S Ratio

-3.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IKNA income statement (TTM)
RevenueUS$27.73m
Cost of RevenueUS$55.54m
Gross Profit-US$27.81m
Other ExpensesUS$21.23m
Earnings-US$49.05m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.35
Gross Margin-100.31%
Net Profit Margin-176.89%
Debt/Equity Ratio0%

How did IKNA perform over the long term?

See historical performance and comparison